Skip to main content

Table 5 Clinical trials of SIRPα targeted agents in solid tumors

From: Targeting macrophages: a novel treatment strategy in solid tumors

Code

Inhibitor type

Conditions

Monotherapy or Combination

Number of patients recruited

Phases stage

Clinical trial NO

CC-95251

Human

Advanced solid and hematologic cancers

Monotherapy, or Combination

230 participants

Phase I

NCT03783403

BI 765,063

(OSE-172)

Humanized

IgG4

Solid tumors

Combination

18 participants

Phase I

NCT04653142

  

Solid tumor, adult

Combination

116 participants

Phase I

NCT03990233

  

HNSCC

melanoma

NSCLC

Combination

22 participants

Phase I

NCT05068102

  

HNSCC

Combination

150 participants

Phase I

NCT05249426

Evorpacept

(ALX148)

mutated SIRPα-Fc IgG1

HNSCC

Combination

168 participants

Phase II

NCT04675333

  

HNSCC

Combination

183 participants

Phase II

NCT04675294

  

HER2 + gastric cancer

Combination

450 participants

Phase II/III

NCT05002127

  

Metastatic cancer;

solid tumor; advanced cancer;

NHL

Combination

174 participants

Phase I

NCT03013218

  

Microsatellite stable

metastatic colorectal cancer

Combination

80 participants

Phase II

NCT05167409

  

HER2-expressing cancers

Combination

93 participants

Phase I/II

NCT05027139

TTI-621

SIRPα-Fc IgG1

R/R solid tumors and mycosis fungoides

Monotherapy,or combination

174 participants

Phase I

NCT02890368

  

Hematologic malignancies solid tumor

Monotherapy,

or combination

250 participants

Phase I

NCT02663518

  

Leiomyosarcoma

Combination

80 participants

Phase I/II

NCT04996004

TTI-622

SIRPα-Fc IgG4

Platinum-resistant ovarian cancer

Combination

50 participants

Phase I/II

NCT05261490